Why the study?
Chronic kidney disease affects over 5% of adults and is associated with hypertension mainly due to perturbation of the renin-angiotensin-aldosterone axis, increasing cardiovascular risk.
Highlights the importance of RAA axis blockade with ACE inhibitors and ARBs in managing hypertension and reducing cardiovascular risk in patients with CKD.
Chronic kidney disease (CKD) is now understood to affect over 5% of all adult patients and it conveys a risk of reduced survival in those affected. At least 80% of those patients with stages 3-5 CKD (i.e. GFR <60 ml/min) suffer with hypertension, and in most the major cause is due to pertubation of an important renal endocrine system, the renin-angiotensin-aldosterone (RAA) axis. In this article the epidemiology of renal-related hypertension and its importance in pre-disposing to the increased cardiovascular risk in renal disease are discussed. Hypertension is known to be a major cause of progressive loss of renal function in CKD, particularly because of activation of the RAA, and hence the case for blockade of this system with ACE inhibitors and Angiotensin receptor blockers is highlighted.
No takes yet. Share an insight, caveat, or question.
P A Kalra (2007) conducted a review in Chronic kidney disease and hypertension. ACE inhibitors and Angiotensin receptor blockers was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: